Please login to the form below

Not currently logged in
Email:
Password:

Larry Bell joins Dutch biopharma Prosensa

Takes up role as head of global regulatory affairs

Prosena Larry BellDutch biopharmaceutical company Prosensa Therapeutics has appointed Larry Bell as head of global regulatory affairs.

He joins the Leiden-based company with more than 18 years of regulatory affairs experience gained at companies that include Merck, Bristol-Myers Squibb, Aventis and Amgen.

Prior to setting up his own consultancy, his most recent role was as vice president and global head of regulatory affairs at GE Healthcare

For his new role at Prosensa, which focuses on RNA-modulating therapeutics for rare diseases with high unmet need, Bell will be based in the US and oversee the company's global regulatory activities.

Bell said: “This is a key time to be joining the Prosensa team. As the orphan drugs space grows in size and scope, there are many regulatory considerations that need to be addressed in order for new drugs to reach the patients that need them.

“I look forward to helping progress Prosensa's cutting-edge therapies through the regulatory process.”

18th February 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....